adakveo
novartis europharm limited - crizanlizumab - anémie, drépanocytose - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
leqvio
novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - agents de modification des lipides - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
tabrecta
novartis europharm limited - capmatinib dihydrochloride monohydrate - carcinome, poumon non à petites cellules - agents antinéoplasiques - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.
locametz
novartis europharm limited - gozetotide - imagerie des radionucléides - produits radiopharmaceutiques de diagnostic - ce médicament est destiné à un usage diagnostique uniquement. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - bénigne de la prostate tumeurs, résistant À la castration - produits radiopharmaceutiques thérapeutiques - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
calciform 500 mg, comprimé effervescent
pluripharm - calcium élément - comprimé - 500 mg - composition pour un comprimé > calcium élément : 500 mg . sous forme de : carbonate de calcium 1250 mg
dualair 50 microgrammes/20 microgrammes par dose, suspension pour inhalation en flacon pressurisé
pluripharm - bromhydrate de fénotérol - suspension - 0,050 mg - composition pour une dose > bromhydrate de fénotérol : 0,050 mg > bromure d'ipratropium anhydre : 0,020 mg . sous forme de : bromure d'ipratropium
isudrine, suspension buvable en flacon
pluripharm - magnésium (oxyde de) - suspension - 0,760 g - composition pour 100 g > magnésium (oxyde de) : 0,760 g > aluminium (phosphate d'), gel de : 61,900 g
motec 15 mg, gélule
pluripharm - méloxicam - gélule - 15 mg - composition pour une gélule > méloxicam : 15 mg
motec 7,5 mg, gélule
pluripharm - méloxicam - gélule - 7,5 mg - composition pour une gélule > méloxicam : 7,5 mg